MEK1/2 Inhibition Rescues Neurodegeneration in Alzheimer’s Disease Models by Enhancing Autophagy
Genuv presented three posters at the Keystone Virtual Symposium “Neurodegenerative Disease: Genes, Mechanisms and Therapeutics,” that show promising preclinical results for our new drug candidate, SNR1611.
In mouse models of Alzheimer’s Disease, SNR1611 showed positive neurogenesis and neuroprotective effects. In one of the studies of a mouse model of Alzheimer’s, orally administered drug led to reduced beta amyloid plaque deposits and recovery of impaired neuronal structures and cognitive functions.
The studies are an important validation of our ATRIVIEW® platform, which screens for compounds that induce differentiation of neurons without neuronal cell death in simulated disease conditions.